About Us

About Us

Rheos Medicines is a biopharmaceutical company developing novel medicines that modulate immune cell metabolism with an initial focus on treating patients with severe autoimmune diseases and cancer.

We are rapidly applying a first-in-field approach in immunometabolism with a comprehensive, systems-biology understanding of the metabolic pathways that drive immune cell function. Launched in 2018 by Third Rock Ventures and pioneers in the field, Rheos is built on groundbreaking science, and our passionate team of more than 30 employees is advancing a novel pipeline of immunometabolism drugs.  We have brought together leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of the heterogeneity of immune-mediated diseases, and an experienced leadership team.

Back to Top